There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC).
In the United States, this form of cancer occurs in approximately 15 000 persons annually. A …

Background & Aims Direct-acting antivirals have become widely used for patients with
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …

Abstract Introduction The Asian Pacific Association for the Study of the Liver (APASL)
convened an international working party on the management of hepatocellular carcinoma …

Although annular fibrosis is the hallmark of cirrhosis, other microscopic changes that affect
liver function such as sinusoid capillarization or loss of metabolic zonation are common. A …

Background & Aims The effectiveness of hepatitis C virus (HCV) treatment with pegylated
interferon and ribavirin usually is evaluated by the surrogate end point of sustained virologic …

BACKGROUND & AIMS: Although the incidence of hepatocellular carcinoma (HCC) is
increasing in the United States, data from large prospective studies are limited. We …

Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis
who achieve a sustained virological response (SVR) have a lower risk of hepatic …

Background: Clinical outcomes of chronic hepatitis C infection in patients with advanced
fibrosis include liver failure, hepatocellular carcinoma, and death. Objective: To investigate …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …